Immunome (NASDAQ:IMNM) Director Sells $8,330,768.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 383,200 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the sale, the director owned 2,031,181 shares in the company, valued at $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Immunome Stock Up 2.8%

Immunome stock opened at $22.34 on Friday. The company has a 50 day moving average of $18.22 and a 200-day moving average of $13.04. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $25.30. The stock has a market capitalization of $2.05 billion, a PE ratio of -7.57 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Equities analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IMNM. MetLife Investment Management LLC grew its holdings in Immunome by 19.1% during the first quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock worth $285,000 after purchasing an additional 6,792 shares during the period. Tema Etfs LLC acquired a new stake in shares of Immunome in the second quarter valued at approximately $1,074,000. Kennedy Capital Management LLC boosted its stake in shares of Immunome by 642.6% during the 2nd quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock worth $1,017,000 after acquiring an additional 94,627 shares during the period. Adage Capital Partners GP L.L.C. increased its holdings in shares of Immunome by 55.0% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock worth $5,216,000 after acquiring an additional 275,000 shares during the last quarter. Finally, Intech Investment Management LLC raised its stake in Immunome by 17.8% in the 2nd quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock valued at $377,000 after acquiring an additional 6,141 shares during the period. Institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on IMNM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Craig Hallum started coverage on shares of Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 price target for the company. Lake Street Capital increased their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $21.00 target price on shares of Immunome in a research report on Friday, November 7th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.09.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.